Evidence map›Paper›PMID 42515047›Full record

ArticlePathogens (Basel, Switzerland)2026

Reassessing Regional Tick-Borne Encephalitis Endemicity in Poland Through Seroprevalence Analysis in Blood Donors, 2021-2022.

Katarzyna W Pancer, Magdalena Rosińska, Gerhard Dobler, Daniel Rabczenko, Agnieszka Kołakowska-Kulesza, Beata Gad, Anna Poznańska, Piotr Grabarczyk

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katarzyna W PancerNational Institute of Public Health NIH-NRI, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0003-3665-5765
Magdalena RosińskaNational Institute of Public Health NIH-NRI, Chocimska 24, 00-791 Warsaw, Poland.
Gerhard DoblerBundeswehr Institute of Microbiology, 80937 Munich, Germany.
Daniel RabczenkoNational Institute of Public Health NIH-NRI, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0002-9746-2003
Agnieszka Kołakowska-KuleszaNational Institute of Public Health NIH-NRI, Chocimska 24, 00-791 Warsaw, Poland.
Beata GadNational Institute of Public Health NIH-NRI, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0003-3702-1297
Anna PoznańskaNational Institute of Public Health NIH-NRI, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0002-2026-7293
Piotr GrabarczykDepartment of Virology, Institute of Heamatology and Transfusion Medicine, 00-791 Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TBEV is a major cause of viral central nervous system infections in Europe, with heterogeneous geographical distribution and substantial underdiagnosis in low-incidence regions. This study aimed to evaluate the validity of regional TBE risk classification in Poland by combining surveillance-based incidence data with serological markers of TBEV exposure. Plasma samples from 5541 blood donors residing in nine regions were tested by anti-TBEV IgG ELISA, followed by confirmatory VNT, IFA, and anti-NS1 IgG ELISA to differentiate infection-induced from vaccine-induced antibodies. Regions were classified based on average TBE incidence registered in surveillance systems in 2015-2019. Overall, 272 (4.9%) donors were positive in TBEV IgG ELISA and 177 (3.2%) also in a confirmatory assay. Seroprevalence expressed by markers consistent with past TBEV infection (anti-NS1 IgG) was estimated at 0.13% (95% CI 0.05-0.26%), ranging from 0.0% to 0.33% by voivodeship, whereas vaccine-induced immunity accounted for the majority of samples with detected specific antibodies (3.1%). Surprisingly, seroprevalence in a highly affected region (0.29%) was at the same level as in one that was less affected (0.33%). Moreover, all except one seropositive donor lived in urban areas. In four out of nine voivodeships, no anti-NS1 TBEV IgG was detected. By utilising precise laboratory algorithms, we demonstrated a much lower seroprevalence that estimated from prior research relying on screening tests. In addition, we confirmed low vaccination coverage. Integrating sero-epidemiological data with surveillance systems may improve risk assessment and inform targeted prevention strategies.

Indexed as

Antibodies, ViralBlood DonorsEncephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneEndemic DiseasesAdolescentAdultBlood DonationEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GIncidenceMaleMiddle AgedPolandAntibodies, ViralImmunoglobulin Gblood donorsinfection-induced antibodiesPolandsurveillanceTBETBEVvaccine-induced antibodies

Identifiers

PMID42515047
PMCPMC13414818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.